Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Health and Human Services Secretary Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce ...

Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Journavx’s pricing strategy, with a daily maintenance cost of $31, positions it at a premium compared to generic alternatives. This could lead to resistance from payers and potentially limit ...

In 10 years, there will probably be a different set of trending topics on The Street, but those changes won't stop the market ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

The success of Journavx will depend on factors such as payer coverage, physician adoption, and its performance relative to existing pain management options, including opioids. In emerging therapeutic ...

L’enquête d'un réseau de journalistes révèle des pratiques douteuses chez Worldline. Les investisseurs ont déserté le titre.